MAPT and Alzheimer disease: Since 2021, four new treatments have achieved US Food and Drug Administration approval (aducanumab, lecanemab, brexpiprazole, and donanemab), and the number and availability of new tools to support research, such as tau positron emission tomography imaging, plasma‐based biomarkers, and innovative biomarkers for non‐AD causes of neurodegeneration, are poised to further accelerate treatment development for all AD/ADRD conditions.